Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive™’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Catch up on CGTLive's coverage of the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held in Dallas, Texas, March 19-22, 2023.
In advance of the upcoming regulatory action deadline for Sarepta Therapuetics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy (DMD), delandistrogene moxeparvovec (also known as SRP-9001), the FDA has determined it will hold an advisory committee (AdComm) meeting.
Janssen is no longer seeking the approval of ciltacabtagene autoleucel (cilta-cel; Carvykti), a chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed/refractory (r/r) multiple myeloma (MM), by the UK’s National Institute of Health and Care Excellence, according to the charity group Myeloma UK.
The FDA has placed Athenex’s autologous GD2 chimeric antigen receptor natural killer T-cell (CAR-NKT) therapy KUR-501 on clinical hold after reports of a patient death in the phase 1 GINAKTI2 study (NCT03294954) assessing the therapy in relapsed/refractory high-risk neuroblastoma
The FDA will hold an advisory committee meeting discussing BrainStorm Cell Therapeutics’ mesenchymal stem cell neurotrophic factor (MSC-NTF) cell therapy NurOwn for the potential treatment of amyotrophic lateral sclerosis (ALS), the company has announced.
The collaboration is intended to provide companies developing gene therapies with necessary consumables and a protocol for the downstream processing workflow.
The Orgenesis Mobile Processing Units and Labs are intended to allow for more cost-effective development of cell and gene therapies at universities and other institutions.
The 3 gene therapies will utilize adeno-associated virus (AAV)-capsid based delivery.
The organization has provided 2 grants with a combined value of approximately $400,000 for the purpose of investigating transgene-triggered safety concerns in gene therapy.
Arsenal Bioscience is developing autologous T-cell therapies for indications including platinum-resistant ovarian cancer.
The newly formed company will focus initial efforts on developing AAV vector-based therapies for monogenic and acquired lung diseases.
The agreement builds upon a previously established collaboration between the 2 companies.
The 2 companies will focus their efforts on discovery and development of new treatments for autoimmune diseases.
Vertex Therapeutics is developing hypoimmune cell therapy products for the treatment of type 1 diabetes.
The company, which received $12.5 million in a recent seed financing round, will seek to develop treatments based on the reprogramming of recombinases.
Canon has announced its intention to expand its Medical Group's activities into the regenerative medicine space.
The agreement includes options for immune cell and liver programs.
Mission Bio will provide use of its Tapestri Platform for cell therapy development processes.
CHM 2101 is an investigational CAR-T therapy intended to treat gastrointestinal and neuroendocrine cancers. Chimeric had a positive pre-IND meeting with the FDA relating to its proposed phase 1 clinical trial.
The 2 organizations will utilize the technology in the collaborative development of a new diabetes treatment.